CAR T cells targeting CD5 for T-cell leukemia or lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune therapy called CAR T cells that are designed to find and attack cancer cells with a CD5 marker. It may be an option for people with T-cell leukemia or lymphoma that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 70 years old.
- You must have a type of T-cell cancer (leukemia or lymphoma) that has come back or hasn't responded to treatment, and your cancer cells have a protein called CD5 on their surface.
- You should be well enough to carry out daily activities (ECOG score 0-2).
- Your major organs, like kidneys, liver, heart, and lungs, must be working well.
- You cannot have a serious active infection, severe autoimmune disease, or have had a stem cell transplant from a donor in the last 3 months.
- You must not have been treated with a therapy that targets the CD5 protein before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.